Provectus Biopharmaceuticals (PVCT) Shares are Down -3.21%

Provectus Biopharmaceuticals (PVCT) : During the past 4 weeks, traders have been relatively bearish on Provectus Biopharmaceuticals (PVCT), hence the stock is down -51.22% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.72% relative to the S&P 500. The 4-week change in the price of the stock is -52.21% and the stock has fallen -3.21% in the past 1 week.

The stock has recorded a 20-day Moving Average of 24.3% and the 50-Day Moving Average is 51.12%.The 200 Day SMA reached 67.95% Provectus Biopharmaceuticals, Inc. has dropped 67.23% during the last 3-month period . Year-to-Date the stock performance stands at -70.59%.


For the current week, the company shares have a recommendation consensus of Buy. Provectus Biopharmaceuticals (NYSEMKT:PVCT): The stock opened at $0.1 and touched an intraday high of $0.1189 on Friday. During the day, the stock corrected to an intraday low of $0.092, however, the bulls stepped in and pushed the price higher to close in the green at $0.1147 with a gain of 16.21% for the day. The total traded volume for the day was 7,959,386. The stock had closed at $0.1147 in the previous trading session.

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. All of its prescription drug candidates are in either the pre-clinical or clinical trial stage. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.